Psoriasis Therapeutics Market in the 7MM is expected to grow during the study period, 2020-2034, estimates DelveInsight

DelveInsight's "Psoriasis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Psoriasis, historical and forecasted epidemiology as well as the Psoriasis therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover Key Insights into the Psoriasis Market with DelveInsight's In-Depth Report @ Psoriasis Market Size [https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Psoriasis Market Research Report

* In December 2024:- Janssen-Cilag International NV- The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of disease until week 68 with prolonged treatment intervals of 16 weeks (guselkumab 100 mg every 16 weeks).
* Psoriasis is prevalent worldwide with a global prevalence of 1% to 8%. It begins in childhood in approximately one-third of cases.
* In 2023, the total number of diagnosed prevalent cases of psoriasis in the US was estimated to be around 8,000,000.
* Among type-specific cases, approximately 68% of the psoriatic patients suffer from plaque psoriasis followed by inverse psoriasis in the US.
* In 2023, approximately 28% of psoriasis patients in the US were estimated to suffer from genital psoriasis, followed by those with scalp psoriasis.
* The most common form of Psoriasis is Plaque Psoriasis, affecting about 90% of psoriasis patients, with about 20%-30% of them suffering from a moderate or severe condition.
* The study by Armstrong et al. (2021) highlighted the prevalence of psoriasis in adults in the US and how prevalence has changed since 2003. As per the findings, the prevalence of psoriasis in adults in the US was 3.0. The study also mentioned that in children younger than 18 years, showed a psoriasis prevalence of 0.128%.
* The leading Psoriasis Companies such as Amgen, Janssen, AbbVie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., Leo Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, Bristol-Myers Squibb, Allergan, Can-Fite Biopharma, Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, Merck, Arbor Pharmaceuticals, Dr. Reddy's Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Affibody AB, Jiangsu HengRui Medicine, Santalis Pharmaceuticals, Astellas Pharma, and Genentech , and others.
* Promising Psoriasis Pipeline Therapies in the various stages of development includes SOTYK TU (deucravacitinib), ZORYVE (roflumilast), VTAMA (tapinarof), Synthetic Hypericin (SGX302), SCD-044, SFA-002 , and others.

Stay ahead in the Psoriasis Therapeutics Market with DelveInsight's Strategic Report @ Psoriasis Market Outlook [https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Psoriasis Epidemiology Segmentation in the 7MM

* Diagnosed Prevalence of Psoriasis in Adults in the US
* Diagnosed Prevalence of Psoriasis by Types in the US
* Diagnosed Prevalence of Psoriasis by Location in the US
* Diagnosed Prevalence of Psoriasis in Pediatrics in the US
* Diagnosed Prevalence of Psoriasis by Severity in the US

Download the report to understand which factors are driving Psoriasis epidemiology trends @ Psoriasis Prevalence [https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Psoriasis Market Outlook

Psoriasis is a chronic relapsing disease, which often necessitates long-term therapy. Disease severity, comorbidities, and healthcare access determine the therapy choice for psoriasis. Psoriatic patients are frequently categorized into two groups: mild or moderate-to-severe psoriasis, depending on the clinical severity of the lesions, the percentage of affected body surface area, and patient quality of life. The market is dominated by TNF inhibitors, interleukin inhibitors, and vitamin D analogs. The market is also driven by the increasing adoption of biologic therapies, growing emphasis on precision medicine, and expanding topical treatment options. The approvals of oral TYK2 inhibitors and nonsteroidal topical agents have further increased the number of psoriasis treatments, making the market more competitive.

Psoriasis Drugs Market Landscape

A range of agents is available for the symptomatic treatment of psoriasis. Patients with mild-to-moderate psoriasis usually receive topical treatments that modulate gene transcription, inhibit cell proliferation and promote keratinocyte differentiation. These cases can be treated topically with glucocorticoids, vitamin D analogs, and phototherapy. Major topical agents include corticosteroids, retinoids such as tazarotene, and calcineurin inhibitors such as tacrolimus, vitamin D analogs such as calcipotriene or calcitriol, and combinations such as calcipotriol plus betamethasone dipropionate.

Get In-Depth Knowledge on Psoriasis Market Trends and Forecasts with DelveInsight @ Psoriasis Treatment Market [https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Psoriasis Companies

Amgen, Janssen, AbbVie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., Leo Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, Bristol-Myers Squibb, Allergan, Can-Fite Biopharma, Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, Merck, Arbor Pharmaceuticals, Dr. Reddy's Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Affibody AB, Jiangsu HengRui Medicine, Santalis Pharmaceuticals, Astellas Pharma, and Genentech, and others.

Scope of the Psoriasis Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Psoriasis Companies- Amgen, Janssen, AbbVie, Novartis, AstraZeneca, Bausch Health, Eli Lilly, Sun Pharmaceutical, Janssen Biotech, UCB Inc., Leo Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, Bristol-Myers Squibb, Allergan, Can-Fite Biopharma, Dermavant Sciences, Pfizer, Arcutis Biotherapeutics, Merck, Arbor Pharmaceuticals, Dr. Reddy's Laboratories, Kadmon Pharmaceuticals, Boehringer Ingelheim, Affibody AB, Jiangsu HengRui Medicine, Santalis Pharmaceuticals, Astellas Pharma, and Genentech, and others.
* Psoriasis Pipeline Therapies- SOTYKTU (deucravacitinib), ZORYVE (roflumilast), VTAMA (tapinarof), Synthetic Hypericin (SGX302), SCD-044, SFA-002, and others.
* Psoriasis Market Dynamics: Psoriasis Market Drivers and Barriers
* Psoriasis Unmet Needs, KOL's views, Analyst's views, Psoriasis Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight's Comprehensive Psoriasis Market Report @ Psoriasis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/psoriasis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Executive Summary of Psoriasis

3. Competitive Intelligence Analysis for Psoriasis

4. Psoriasis: Market Overview at a Glance

5. Psoriasis: Disease Background and Overview

6. Patient Journey

7. Psoriasis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Psoriasis Unmet Needs

10. Key Endpoints of Psoriasis Treatment

11. Psoriasis Marketed Products

12. Psoriasis Emerging Therapies

13. Psoriasis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Psoriasis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psoriasis-therapeutics-market-in-the-7mm-is-expected-to-grow-during-the-study-period-20202034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.